AstraZeneca's Tagrisso gets broader U.S. FDA nod for lung cancer
Duluth, MN, USA / 710 AM 98.1 FM WDSM Dec 21, 2020 1:39 AM (Reuters) -AstraZeneca Plc said on Monday that the U.S. drug regulator had approved Tagrisso, the British drugmaker's top selling treatment for another type of lung cancer when diagnosed at an early stage, pushing its potential sales higher. The lung cancer drug has now been approved in the United States for adjuvant treatment of adults diagnosed early enough for the tumour to be surgically removed, and who have a mutation of the EGFR gene, AstraZeneca said. The approval by the U.S. Food and Drug Administration was based on late-stage...